Benralizumab, dupilumab, and reslizumab are mAbs to IL-5R, IL-4R, and IL-5, respectively, the biologics currently approved worldwide for allergic diseases such as asthma and atopic dermatitis.24 This evidence concerns the gene IL5 and asthma.